NUCALA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE PTE LTD

Therapeutic

Prescription Only

INJECTION, SOLUTION

**Dosage and Administration** Pharmaceutical form: Solution for injection in a pre-filled pen (auto-injector) Solution for injection in a pre-filled syringe (safety syringe) _NUCALA_ should only be administered as a subcutaneous injection (see _Use and Handling and Instructions for Use_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). _NUCALA_ may be self-administered by the patient or administered by a caregiver if their healthcare professional determines that it is appropriate and the patient or caregiver are trained in injection techniques. **Populations** **Severe Eosinophilic asthma** **Adults and Adolescents (12 years and older)** The recommended dose is 100 mg of _NUCALA_ administered by subcutaneous (SC) injection once every 4 weeks. **CRSwNP** **Adults** The recommended dose is 100 mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks. **Children** Use in patients less than 18 years of age is not relevant for CRSwNP. **EGPA** Injection sites should be at least 5 cm apart (see _Use and Handling_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Adults** The recommended dose is 300 mg of _NUCALA_ administered by subcutaneous (SC) injection once every 4 weeks. EGPA: _NUCALA_ is not indicated in patients under 18 years of age. **Children (up to 12 years of age)** The safety and efficacy of _NUCALA_ have not been established in children less than 12 years of age. **HES** Injection sites should be at least 5 cm apart (see _Use and Handling_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Adults** The recommended dose is 300 mg of _NUCALA_ administered by subcutaneous (SC) injection once every 4 weeks. **Children** The safety and efficacy of _NUCALA_ have not been established in children. **Elderly (65 years or older)** No dosage adjustment is recommended in patients 65 years or older (see _Pharmacokinetics – Special Patient Populations_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Renal Impairment** Dose adjustments in patients with renal impairment are unlikely to be required (see _Pharmacokinetics – Special Patient Populations_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Hepatic Impairment** Dose adjustments in patients with hepatic impairment are unlikely to be required (see _Pharmacokinetics – Special Patient Populations_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).